Skip to main content
AAWH
OTC Life Sciences

Ascend Wellness Reports Significant FY25 Net Loss Amid Revenue Decline and $17M Arbitration Settlement

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$0.5
Mkt Cap
$101.135M
52W Low
$0.26
52W High
$1.2
Market data snapshot near publication time

summarizeSummary

Ascend Wellness Holdings reported a substantial net loss of $118.2 million for fiscal year 2025 and $48.7 million for Q4 2025, alongside a year-over-year revenue decline, impacted by a $17.0 million arbitration settlement.


check_boxKey Events

  • Significant Net Loss Reported

    The company reported a net loss of $48.7 million for Q4 2025 and $118.2 million for the full year 2025, a substantial increase from the prior year.

  • Revenue Decline

    Total net revenue decreased to $120.5 million in Q4 2025 (3.4% sequential decline) and $500.6 million for FY 2025 (10.9% year-over-year decline).

  • Arbitration Settlement Impact

    A $17.0 million arbitration settlement expense was recorded in Q4 2025, significantly impacting the net loss.

  • Operational Expansion Continues

    Ascend Wellness expanded its retail footprint to 48 locations with 8 new openings in 2025 and launched a record 566 new SKUs.


auto_awesomeAnalysis

This 8-K details Ascend Wellness Holdings' Q4 and full-year 2025 financial results, revealing significant net losses that far exceed the company's market capitalization, primarily driven by a $17.0 million arbitration settlement and ongoing pricing pressures. While the company demonstrated operational progress with new store openings, SKU launches, and improved Adjusted EBITDA margins, the substantial net losses and revenue decline highlight persistent profitability challenges. The Q1 2026 outlook anticipates further revenue decline, suggesting continued headwinds. Investors should monitor the company's ability to translate operational growth into sustainable profitability and manage its debt obligations given the current financial performance.

At the time of this filing, AAWH was trading at $0.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $101.1M. The 52-week trading range was $0.26 to $1.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AAWH - Latest Insights

AAWH
Mar 20, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
7
AAWH
Mar 12, 2026, 5:21 PM EDT
Filing Type: 10-K
Importance Score:
9
AAWH
Mar 12, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
8
AAWH
Feb 13, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
8
AAWH
Feb 09, 2026, 8:13 AM EST
Filing Type: 8-K
Importance Score:
8
AAWH
Feb 06, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
9